CN117480182A - 抗s100a4人源化抗体、用途和方法 - Google Patents

抗s100a4人源化抗体、用途和方法 Download PDF

Info

Publication number
CN117480182A
CN117480182A CN202280013560.3A CN202280013560A CN117480182A CN 117480182 A CN117480182 A CN 117480182A CN 202280013560 A CN202280013560 A CN 202280013560A CN 117480182 A CN117480182 A CN 117480182A
Authority
CN
China
Prior art keywords
antibody
seq
ser
region
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280013560.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·海伦
R·I·侯赛因
J·克林格霍夫
T·巴斯
D·麦卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alex Therapeutics Co ltd
Original Assignee
Alex Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Therapeutics Co ltd filed Critical Alex Therapeutics Co ltd
Publication of CN117480182A publication Critical patent/CN117480182A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202280013560.3A 2021-02-09 2022-02-09 抗s100a4人源化抗体、用途和方法 Pending CN117480182A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147483P 2021-02-09 2021-02-09
US63/147,483 2021-02-09
PCT/EP2022/053095 WO2022171656A1 (en) 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods

Publications (1)

Publication Number Publication Date
CN117480182A true CN117480182A (zh) 2024-01-30

Family

ID=80446273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280013560.3A Pending CN117480182A (zh) 2021-02-09 2022-02-09 抗s100a4人源化抗体、用途和方法

Country Status (8)

Country Link
US (2) US20240043521A1 (https=)
EP (1) EP4291579A1 (https=)
JP (1) JP7824969B2 (https=)
CN (1) CN117480182A (https=)
AU (1) AU2022219476A1 (https=)
CA (1) CA3207703A1 (https=)
IL (1) IL304971A (https=)
WO (1) WO2022171656A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531230A (ja) * 2020-06-30 2023-07-21 アークス セラピューティクス エーエス 全身性硬化症の治療のための抗ｓ１００ａ４抗体
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN115819577A (zh) * 2022-10-08 2023-03-21 河南赛诺特生物技术有限公司 一种抗s100a单克隆抗体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2580240T (pt) 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos
GB201219487D0 (en) * 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
IL263272B2 (en) * 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用

Also Published As

Publication number Publication date
EP4291579A1 (en) 2023-12-20
IL304971A (en) 2023-10-01
US12304949B2 (en) 2025-05-20
JP2024509701A (ja) 2024-03-05
CA3207703A1 (en) 2022-08-18
JP7824969B2 (ja) 2026-03-05
AU2022219476A1 (en) 2023-09-21
WO2022171656A1 (en) 2022-08-18
US20250092125A1 (en) 2025-03-20
US20240043521A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
CN115003333B (zh) Pvrig结合蛋白及其医药用途
JP2024059872A (ja) 新規抗ｃｃｒ８抗体
KR20240018579A (ko) B7h3 단클론 항체군 및 그 의약적 용도
CN114560941B (zh) Cldn18.2的抗体及其应用
JP2020514363A (ja) 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
WO2022002036A1 (zh) 一种双特异性抗体及其用途
JP2025041695A (ja) 抗体および使用方法
US20230174670A1 (en) Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
CN111683680B (zh) 抗rspo3抗体
CN116547300B (zh) 双特异性抗体及其应用
CN113307874B (zh) 一种抗lag3的抗体及其应用
TW202423987A (zh) 抗ccr8抗體及其應用
KR20240006519A (ko) 항-siglec 조성물 및 이의 용도
KR20230015331A (ko) 항-cd47 항체 및 그의 용도
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN118772279B (zh) 抗FGFR2b抗体或其抗原结合片段及其用途
WO2025153079A1 (en) Method of treatment
RU2782462C1 (ru) Новое антитело против ccr8
CN118240092A (zh) 一种抗pd-l1和tigit双特异性抗体融合蛋白及其应用
CN116848144A (zh) 抗pd-l1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination